396 476
Table 4 – Persistence and adherence: mirabegron versus antimuscarinic agents other than tolterodine ER in all patients (unmatched analysis)
Variable
Mirabegron
(
n
= 1203)
Darifenacin
(
n
= 126)
Fesoterodine
(
n
= 1287)
Flavoxate
(
n
= 144)
Oxybutynin
ER (
n
= 1144)
Oxybutynin
IR (
n
= 5779)
Propiverine
(
n
= 95)
Solifenacin
(
n
= 8191)
Tolterodine
IR (
n
= 1523)
Trospium
chloride
(
n
= 943)
Persistence
Time to discontinuation (d)
Median (IQR)
169 (41–NR) 56 (28–179)
78 (28–353)
30 (30–64)
60 (30–208)
35 (28–108)
56 (28–258)
67 (30–366)
56 (28–285)
60 (28–237)
Hazard ratio (95% CI)
a–
1.76 (1.44–2 .15) 1.37 (1.25–1.51) 2.26 (1.88–2.71) 1.46 (1.32–1.60) 1.90 (1.76–2.05) 1.66 (1.31–2.09) 1.24 (1.15–1.34) 1.59 (1.45–1.74) 1.57 (1.43–1.74)
p
value
–
<
0.0001
<
0.0001
<
0.0001
<
0.0001
<
0.0001
<
0.0001
<
0.0001
<
0.0001
<
0.0001
12-mo persistence,
n
(%)
454 (38)
20 (16)
309 (24)
12 (8.3)
197 (17)
719 (12)
20 (21)
2028 (25)
313 (21)
180 (19)
Difference, % (95% CI)
–
22 (15–29)
14 (10–17)
30 (24–35)
21 (17–24)
25 (23–28)
17 (8–25)
13 (10–16)
17 (14–21)
19 (15–22)
Odds ratio (95% CI)
a–
0.35 (0.21–0.57) 0.60 (0.50–0.72) 0.19 (0.10–0.34) 0.45 (0.37–0.54) 0.33 (0.28–0.38) 0.45 (0.27–0.75) 0.74 (0.65–0.85) 0.48 (0.40–0.57) 0.42 (0.34–0.51)
p
value
–
<
0.0001
<
0.0001
<
0.0001
<
0.0001
0.002
<
0.0001
<
0.0001
<
0.0001
<
0.0001
Adherence
Patients (
n
)
955
73
822
46
651
2775
55
5208
909
591
MPR
Mean (SD)
b0.59 (0.33)
0.46 (0.34)
0.53 (0.33)
0.44 (0.32)
0.49 (0.32)
0.41 (0.32)
0.51 (0.32)
0.53 (0.34)
0.50 (0.34)
0.48 (0.33)
p
value
–
0.002
0.001
0.004
<
0.0001
<
0.0001
0.07
<
0.0001
<
0.0001
<
0.0001
Adherent patients,
c n(%) 410 (43)
21 (29)
286 (35)
11 (24)
202 (31)
621 (22)
14 (25)
1846 (35)
291 (32)
169 (29)
Difference, % (95% CI)
–
14 (3–25)
8 (4–13)
19 (6–32)
12 (7–17)
21 (17–24)
18 (6–30)
8 (4–11)
11 (7–15)
14 (10–19)
p
value
–
0.02
0.0005
0.01
<
0.0001
<
0.0001
0.01
<
0.0001
<
0.0001
<
0.0001
Median follow-up (d)
d525
514
551
627
559
548
575
562
533
562
CI = confidence interval; ER = extended release; IQR = interquartile range; IR = immediate release; MPR = medication possession ratio; NR = not reached; SD = standard deviation.
a
Adjusted for gender, age group, treatment status, Charlson comorbidity index, hypertension, and polypharmacy at the index date.
b
MPRs ranged from 0 (no adherence) to 1 (perfect adherence).
c
Patients considered to be adherent when MPR 0.8.
d
Patients who did not discontinue treatment 12 mo after initiation.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 8 9 – 3 9 9
396